Search
Invitrogen
Ranitidine Recombinant Mouse Monoclonal Antibody (4G7)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
图: 1 / 1
Ranitidine Antibody (MA566337) in SDS-PAGE
SDS-PAGE characterization of Ranitidine under reducing conditions. Lane M: Protein marker (kDa); Lane RNTD: Purified Ranitidine Recombinant Monoclonal (Product # MA566337). Ranitidine showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-639.
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
产品信息
MA566337
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4G7
抗原
Conjugate of RNTD hapten and KLH.
偶联物
Unconjugated
Unconjugated
Unconjugated
形式
Liquid
浓度
5.2 mg/mL
规格
200 µg
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
RRID
靶标信息
Ranitidine, a histamine H2-receptor antagonist, is primarily used to reduce stomach acid production and treat conditions such as gastroesophageal reflux disease (GERD). The gene encoding ranitidine's target, the H2 receptor, is located on chromosome 3p25.3. Structurally, ranitidine is characterized by a furan ring linked to a nitroethenediamine moiety, which facilitates its binding to the H2 receptor, thereby inhibiting histamine-induced gastric acid secretion. The biosimilar development of ranitidine involves synthesizing analogs with structural modifications to enhance binding affinity and therapeutic efficacy, as explored through molecular modeling and structure-activity relationship studies. These modifications aim to optimize interactions with the receptor's hydrophobic and peripheral anionic sites, ensuring effective inhibition of gastric acid secretion. The bioavailability of ranitidine formulations is assessed through comparative studies, ensuring that biosimilars match the pharmacokinetic profiles of reference products like Zantac.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
